Dermatology - European Medical Journal

Continue

Dermatology

Filter
9 Mins
13 Dec 2018

Chronic Spontaneous Urticaria in Patients with Common Variable Immunodeficiency

Common variable immunodeficiency (CVID) is a predominantly antibody deficiency and is one of the most common primary…
10 Mins
30 Oct 2018

PASI 90/100, DLQI 0/1, and IL-17 Receptor/Cytokine: Does it Make a Difference and Are We Ambitious Enough?

The main objectives of the symposium were to review recent evidence on what difference targeting Psoriasis Area Severity Index (PASI) 90 or 100 and…
9 Mins
30 Oct 2018

Navigating the Road to Psoriasis Control in Women: Strategies to Optimise the Reproductive Journey

The importance of discussions around the management of women of childbearing age with psoriasis, an issue that has been largely neglected for many years…
10 Mins
30 Oct 2018

Is Complete Skin Clearance in Psoriasis the Answer?

Prof Reich outlined the new understanding of psoriasis pathogenesis, with IL-23 rather than IL-12 considered the pivotal cytokine pathway. This…
9 Mins
30 Oct 2018

IL-23 Inhibition in Psoriasis: Changing the Present, Shaping the Future

This symposium took place at the 27th European Academy of Dermatology and Venereology (EADV) Congress. The session examined the latest data for…
9 Mins
30 Oct 2018

From Evolution to Revolution: IL-23 in the Treatment of Psoriasis Patients

This symposium, which took place during the 2018 meeting of the European Academy of Dermatology and Venereology (EADV) in Paris, France, provided…
10 Mins
30 Oct 2018

Emerging Insights in the Treatment of Psoriasis and Psoriatic Arthritis

Guselkumab is a monoclonal antibody targeting IL-23 that is approved for the treatment of patients with moderate-to-severe plaque psoriasis. Two of…
9 Mins
30 Oct 2018

Efficacy, Sustainability, and Patient-Reported Outcomes of Guselkumab to Treat Plaque Psoriasis in the Post-Approval Setting

Plaque psoriasis is an autoimmune condition characterised by the development of red, dry, scaly skin lesions that cause irritation and pain for patients…
We’ve noticed you’re accessing
from North/South America.